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Edited by Judit Ova`diAbstract The parasitic helminth Fasciola hepatica secretes a 2-
Cys peroxiredoxin (Prx) that may play important functions in
host–parasite interaction. Recombinant peroxiredoxin (FhePrx)
prevented metal-catalyzed oxidative nicking of plasmid DNA
and detoxiﬁed hydrogen peroxide when coupled with Escherichia
coli thioredoxin and thioredoxin reductase (kcat/Km = 5.2 ·
105 M1 s1). Enzyme kinetic analysis revealed that the cata-
lytic eﬃciency of FhePrx is similar to other 2-Cys peroxiredox-
ins; the enzyme displayed saturable enzyme Michaelis–Menten
type kinetics with hydrogen peroxide, cumene hydroperoxide
and t-butyl hydroperoxide, and is sensitive to concentrations of
hydrogen peroxide above 0.5 mM. Like the 2-Cys peroxiredox-
ins from a related helminth, Schistosoma mansoni, steady-state
kinetics indicate that FhePrx exhibits a saturable, single dis-
placement-like reaction mechanism rather than non-saturable
double displacement (ping–pong) enzyme substitution mechanism
common to other peroxiredoxins. However, unlike the schisto-
some Prxs, FhePrx could not utilise reducing equivalents sup-
plied by glutathione or glutathione reductase.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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hepatica1. Introduction
Peroxiredoxins (Prx) are a ubiquitous family of peroxidases
that reduce hydrogen peroxide to water and alkyl hydroperox-
ides to alcohols [4,5,17,24,33]. At least in bacteria (AhpC),
yeast (thioredoxin peroxidase), and trypanosomatids (trypare-
doxin peroxidase) Prxs are central in the defence against reac-
tive oxygen species (ROS) and protect these cells from
oxidative stress [17,33]. More recent studies indicate that these
enzymes also function intracellularly [32] and extracellularly
[12] in the regulation of H2O2-mediated cell-signalling events
in eukaryotes.Abbreviations: Prx, peroxiredoxin; ES, excretory–secretory products
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doi:10.1016/j.febslet.2006.08.019The catalytic cycle begins with oxidation by the peroxide
substrate of the essential peroxidatic cysteine, the N-terminal
proximal active site Cys, forming a Cys-sulfenic acid deriva-
tive. The intermediate is resolved by a condensation reaction
when Cys-sulfenic acid reacts with a Cys in the C-terminal
distal domain of a second inverted Prx molecule, thus forming
a dimer linked by two disulﬁde bridges [17,33]. Reduction of
the Prx dimer regenerates the Prx monomer and in most cases
the physiological hydrogen donor is thioredoxin, but this
may also be performed by tryparedoxin or glutathione [17].
Thioredoxin itself is maintained in the reduced state by elec-
trons transferred from NADPH by thioredoxin reductase
[4,5,21,33].
The liver ﬂuke, Fasciola hepatica, is an important helminth
pathogen of humans and livestock [8,11,22]. Infective parasites
(metacercariae) excyst from a dormant state following inges-
tion and penetrate the intestinal wall before migrating to the
liver. In this nutrient and oxygen rich environment the para-
sites undergo rapid growth and development, and energy is
supplied by aerobic respiration [9,31]. As part of its antioxi-
dant defence, F. hepatica expresses glutathione-S-transferase
and superoxide dismutase, which detoxify ROS to hydrogen
peroxide [1,2,21]. The pathway of hydrogen peroxide detoxiﬁ-
cation is unclear, since the liver ﬂuke lacks catalase and exhib-
its little glutathione peroxidase activity [1,2,24]. Our
laboratory was the ﬁrst to describe the presence of Prxs in hel-
minth parasites when we reported the isolation of a cDNA
encoding this enzyme in F. hepatica [23]. Since these enzymes
can detoxify hydrogen peroxide we suggested that Prx per-
forms this function in F. hepatica, and other helminths that
lack catalase [23,24].
Here we report the biochemical characterisation of a func-
tionally active recombinant F. hepatica 2-Cys peroxiredoxin
(FhePrx). We show its protective eﬀects against hydrogen per-
oxide in a mixed-function oxidation assay, and by coupling
FhePrx with Escherichia coli thioredoxin and thioredoxin
reductase determined the speciﬁc activity and reaction kinetics
of the enzyme. FhePrx displays saturable, Michaelis–Menten
type kinetics when assayed at low concentrations of substrate
but is sensitive, rather than robust, to over-oxidation by
hydrogen peroxide. The FhePrx does not accept reducing
equivalents from glutathione or glutathione reductase, which
is in contrast to Prx from the related parasite Schistosoma
mansoni.blished by Elsevier B.V. All rights reserved.
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2.1. Parasite materials, proteins and RNA extraction
Adult F. hepatica were recovered from the bile ducts of sheep
experimentally challenged for 14 weeks with 200 infective metacerca-
riae. Soluble extracts were prepared by three cycles of freeze-thaw at
20 C and sonication for 30 s in a soni-bath. Extracts were centrifuged
at 14000 · g for 30 min, the supernatant decanted and stored at80 C.
Excretory–secretory (ES) products were prepared by culturing parasites
in RPMI-1640, containing 30 mMHEPES, 1% glucose and gentamycin
(25 lg/ml) for 6 h. The culture medium was concentrated to 1 mg/ml on
aCentricon (Amicon) with a 3000 Damolecular size cutoﬀ. The cysteine
protease inhibitor E-64 (ﬁnal concentration 1 mM) was added to
parasite extracts and ES products to prevent degradation by parasite
cysteine proteases. Juvenile parasites were excysted from infective meta-
cercaria as previously described [3,8]. Following a single freeze-thaw
cycle at80 C, the parasites were homogenized in Tris-reagent (Sigma)
and total RNA extracted according to the manufacturers’ speciﬁca-
tions. For reverse transcription-PCR (RT-PCR), ﬁrst strand cDNA
was produced with oligo (dT) primers from 2 lg of total RNA by using
avian myeloblastosis virus reverse transcriptase (Promega, Madison,
WI) at 42 C for 60 min. A 5-ll aliquot of the resultant cDNA was
ampliﬁed by using primers speciﬁc for b-actin (mouse, Stratagene, La
Jolla, CA) or Prx (FhePrx fwd and FhePrx rev, see Section 2.3) under
the following conditions: 30 s denaturation at 95 C, 5 s annealing of
primers at 55 C, and 12 s elongation at 72 C for 40 cycles [13].2.2. Preparation of anti-peroxiredoxin serum
Sheep were vaccinated three times with 100 lg of puriﬁed recombi-
nant FhePrx at three week intervals using Quil A (100 lg per sheep)
as an adjuvant. Antigen and adjuvant were formulated in 2 ml sterile
phosphate buﬀered saline (PBS), pH 7.3, and injected sub-cutaneously
in the neck region.
2.3. Cloning and functional expression of F. hepatica peroxiredoxin
(FhePrx)
The FhePrx gene was PCR ampliﬁed from cDNA isolated from a
kgt 11 library immunoscreened with sera from cattle protectively vac-
cinated with a high molecular mass fraction from adult liver ﬂuke
(GenBank Accession No. U88577) [8,23]. The primers used to amplify
the gene were FhePrx Forward: 5 0CCGGAATTCATGTTGCAGCC
T3 0, which inserted an EcoRI site (underlined) proximal to the ATG
start codon of the Prx open reading frame and FhePrx Reverse:
5 0CGGCTCGAGTCACTAGTTGGCTGA3 0 which inserted an XhoI
site (underlined) proximal to a double stop codon. The full length
cDNA corresponds to the 580 nucleotide open reading frame described
in McGonigle et al., [23], initiating with the amino acid residues,
MLQPN – and terminating with the residues – FSSAN, resulting in
a polypeptide of 194 amino acid residues. The full length recombinant
protein has an additional N-terminal 6X Histidine tag and a recombi-
nant tobacco etch virus protease cleavage site.
Sequence accuracy was checked (GATC Biotech, Konstanz, Ger-
many) and the cDNA was inserted into the pPRO Ex HtA vector (Life
Sciences) and used to transform E. coli BL21 (DE3). Recombinant
FhePrx protein was induced with IPTG (1 mM) and extracted using
a method modiﬁed from that described by Frangioni and Neel [15];
bacterial pellets were resuspended in 10 ml STE (150 mM NaCl,
10 mM Tris–HCl, pH 8.0, and 1 mM EDTA) with lysozyme (10 lg/
ml) and kept on ice for 15 min. DTT (10 lg/ml) and N-laurylsarcosine
(0.5%) were added and solution was sonicated for 1 min in a water
bath then centrifuged for 5 min at 4000 rpm to clarify. Triton X-100
(2%), DNase (75 lg/ml) and RNase (10 lg/ml) were added, and the
solution was kept on ice for 15 min. Five volumes of buﬀer (50 mM
sodium phosphate, pH 8.0, 300 mM NaCl and 10 mM imidazole) were
added and the solution was passed through a 0.8 lm ﬁlter (Sartorius).
Recombinant FhePrx was puriﬁed on Ni2+ NTA resin using the non-
denaturing protocol detailed by the manufacturer (Qiagen). Protein
concentration was determined by BCA (Pierce) and purity was deter-
mined by SDS–PAGE.
2.4. Protection of plasmid DNA from nicking
Plasmid pGEM 3zf (Promega) was prepared using a miniprep kit
(Qiagen). DNA protection assays were performed by pre-incubating
recombinant FhePrx with dithiothreitol (DTT) (8 mM) and FeCl3(0.8 mM) for 10 min prior to adding 300 ng of plasmid DNA. The
reactions were incubated for 2.5 h at 37 C and then analysed on a
0.8% agarose gel [20].
2.5. Kinetic analysis of recombinant F. hepatica peroxiredoxin
The speciﬁc activity of FhePrx was determined by the reduction of
H2O2 in a reaction containingE. coli thioredoxin and thioredoxin reduc-
tase (Sigma–Aldrich). The reaction mix contained 5 mM potassium
phosphate, pH 7.0, 1 mM EDTA, 0.25 mM NADPH, 10 lM E. coli
thioredoxin and 0.15 lM E. coli thioredoxin reductase in a total
volume of 500 ll. Consumption of NADPH at 22 C was monitored
at A340 for 1 min in a spectrophotometer after adding hydrogen
peroxide. The speciﬁc activity of the FhePrx was determined by the
following equation: units of Prx/mg of protein = {[(DA/DT · Vt)/
(6.22 · Vs)] · 1000}/[protein] in mg/ml, where 6.22 = extinction
coeﬃcient of NADPH (mM1 cm1), Vt is the total reaction volume,
Vs is the sample volume and 1000 is used to convert to nanomoles
[4,5,19]. Steady-state kinetic analysis was performed using the same as-
say; however, concentrations of thioredoxin ranged from5 lMto20 lM
and hydrogen peroxide ranged from 25 lM to 100 lM. Km and kcat
values were determined using Enzpack for Windows, version 1.4
(Biosoft Software for Science).3. Results and discussion
3.1. Puriﬁcation of recombinant F. hepatica peroxiredoxin
Puriﬁed recombinant FhePrx migrated at an approximate
molecular weight of 26 kDa when analysed by reducing
SDS–PAGE, which agrees with the molecular weight of the
FhePrx predicted from the deduced amino acid sequence,
21.6 kDa [23] plus the 6X His-tag (Fig. 1). When examined
by SDS–PAGE under non-reducing conditions, the FhePrx en-
zyme migrated close to the 50 kDa molecular size marker indi-
cating that the recombinant protein forms a dimeric enzyme
containing a reactive center (Fig. 1B, lane 1). This was con-
ﬁrmed ﬁrstly by reduction of the inter-subunit disulﬁde
bridges, and thereby splitting the two monomers, by addition
of a small dithiol, DTT, to the sample prior to electrophoresis
(Fig. 1B, lane 2). Addition of hydrogen peroxide to the recom-
binant FhePrx caused the dimer to migrate as two bands, one
slightly slower than that seen in lane 1, presumably because
either one or two covalent disulﬁde linkages were formed
between the monomers with corresponding conformation rear-
rangements (Fig. 1B, lane 5) [16]. However, somewhat surpris-
ingly, the addition of DTT before or after the addition of
hydrogen peroxide to the recombinant FhePrx (Fig. 1B, lanes
3 and 4) did not increase the amount of monomeric form. It
was expected that the reduced active site residues, Cys-SH,
would react with the hydrogen peroxide to form the sulfenic
acid derivative, Cys-SOH, which is resolved by dimerisation,
and that addition of DTT should reduce the disulﬁde bonds
to give rise to a monomeric form; however, this did not occur
and the protein migrated similarly to that observed when
hydrogen peroxide was added alone (Fig. 1B, compared lanes
3 and 4 with 5). It is possible that under the experimental con-
ditions hydrogen peroxide reacted directly with DTT and pre-
vented its capacity to reduce the active site cysteines. Dimer
formation was also conﬁrmed by gel permeation chromatogra-
phy which showed that recombinant FhePrx eluted at a mole-
cular weight of approximately 50 kDa (data not shown). Gel
permeation chromatography also detected high molecular
sized forms of the FhePrx (not shown) and some material is re-
tained on the top of the gels lanes in the non-reducing SDS–
PAGE analysis that is reducible by DTT (Fig. 1B, see lanes
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Fig. 1. Production and puriﬁcation of FhePrx under reducing (A) and
non-reducing (B) conditions. (A) Total soluble bacterial extract from
induced FhePrx culture (1); run-through from Ni-NTA resin column
(2), and eluted recombinant FhePrx (3). (B) Recombinant FhePrx (1),
recombinant FhePrx incubated with 0.5 mM DTT for 20 min before
loading (2), recombinant FhePrx incubated with 0.5 mM DTT for
10 min before addition of 0.5 mM hydrogen peroxide for a further
10 min (3), recombinant FhePrx incubated with 0.5 mM hydrogen
peroxide for 10 min before addition of 0.5 mM DTT for a further
10 min (4), and recombinant FhePrx incubated with 0.5 mM hydrogen
peroxide for 20 min. MW, molecular weight markers.
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FhePrx which is known to exist for other Prxs, and is impor-
tant in regulating the activity of the enzymes [17,33].
Using antibodies prepared against recombinant FhePrx we
identiﬁed a single band migrating at an apparent molecular
size of approximately 26 kDa in immunoblots of soluble
extracts of F. hepatica that co-migrated with a major band in
the Coomassie-stained extract (Fig. 2A and B, compare lane
1). A band of similar size was also detected in parasite ES
products of F. hepatica (Fig. 2A and B, lane 2) but is not a
major component of this preparation; the two major bands
observed in the ES products following Coomassie staining
are two previously characterised cathepsin L cysteine proteases
that have similar molecular sizes to FhePrx [7,8]. The native
FhePrx proteins detected in the parasite extracts and ES prod-
ucts co-migrated with the recombinant FhePrx protein
(Fig. 2A and B, lane 3) and also formed dimers under non-reducing conditions (not shown). Pre-immune sheep sera did
not detect any bands (data not shown). Due to the paucity
of material that can be obtained from metacercariae we could
not detect FhePrx by immunoblotting; however, RT-PCR
using total mRNA isolated from these showed that the Prx
is expressed by this infective parasite stage (Fig. 2C).
These data suggest that FhePrx is abundant in F. hepatica
but whether the protein is actively secreted into the medium
by the parasite is not known. Prxs do not possess signal
sequences and are not normally secreted by mammalian cells
[17]; however, in certain infectious situations, such as severe
acute respiratory syndrome [6], HIV infection [16], and in
non-small cell lung cancer [5] extracellular human Prx has
been detected in serum samples. Moreover, FhePrx may
appear in the ES products due to the continual sloughing
and replacement of the parasite tegumental and/or intestinal
cells [9]. We investigated the possibility that FhePrx is a non-
classically secreted protein using the SecretomeP 2.0 server
[www.cbs.dtu.dk/services/SecretomeP/, Ref. 14]. The analysis
of FhePrx returned a value of 0.527, compared to a threshold
value of 0.5, which indicates it is possible that the enzyme is
secreted without a signal peptide, but the probability is not
high. In contrast, a similar analysis of the schistosome egg
Prx (Genbank Accession No. AF121199) which is known to
be secreted returned a value of 0.622, indicating a higher prob-
ability of secretion. FhePrx is expressed by all stages of the
developing parasite, including the earliest infectious larvae,
and antibodies are detected in serum both during acute infec-
tion and at low levels in chronic disease (not shown).3.2. Antioxidant activity of recombinant F. hepatica
peroxiredoxin
In the mixed-function oxidation assay, reactive oxygen spe-
cies are produced in the presence of FeCl3, leading to strand
breaks in super-coiled plasmid DNA that can be visualised
by the formation of slower migrating nicked, open circular
plasmid in agarose gels [20] (Fig. 3A, compare lanes 2 and
3). Addition of recombinant FhePrx with DTT to the reaction
tube protected the plasmid from nicking (Fig. 3A, lane 4), since
this did not occur when DTT was substituted by ascorbic acid
(Fig. 3A, lane 5) the activity of FhePrx is, therefore, thiol-
dependent. The anti-nicking activity was FhePrx-speciﬁc, as
another F. hepatica recombinant protein, cathepsin L1 [7],
did not protect plasmid DNA from nicking (Fig. 3A, lane 6).
Although cathepsin L1 was expressed in the yeast Pichia pas-
toris, the active enzyme is His-tagged and was puriﬁed in an
identical manner to FhePrx. Also, incubation of the plasmid
DNA with another E. coli-expressed recombinant protein,
the surface antigen of Toxoplasma gondii, gave the same result
as the cathepsin L1 negative control. Our data supports that of
Salazar-Calderon and coworkers [28] who demonstrated that a
recombinant F. hepatica thioredoxin peroxidase fused to GST
was able to protect inactivation of glutamine synthetase and
enolase when subjected to FeCl3-induced oxidative stress.
To determine the speciﬁc activity of recombinant FhePrx,
the enzyme was coupled with E. coli thioredoxin and thiore-
doxin reductase in an NADPH oxidation assay. In this
assay recombinant FhePrx exhibited a speciﬁc activity of
1200 nmole/min/mg. Exclusion of any of the three proteins
from the assay resulted in no signiﬁcant consumption of
NADPH (Fig. 3B) although a low level of activity was
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Fig. 2. Expression of FhePrx by parasitic stages in SDS–PAGE (A), immunoblotting (B) and RT-PCR (C). (A) Soluble extract of adult F. hepatica
(1), adult F. hepatica ES products (2), and recombinant FhePrx (3). (B) Arrangement of lanes as for (A), anti-Prx sera was raised in sheep. (C)
Expression of FhePrx and actin (control) in infective larvae (1) and adult F. hepatica (2) was analysed by RT-PCR with gene-speciﬁc primers.
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Fig. 3. Enzymatic activity of recombinant FhePrx, FhePrx protects plasmid DNA from oxidative nicking (A) and speciﬁc activity determined by
NADPH consumption assay (B). (A) Molecular weight markers (1), plasmid pGEM 3zf only (2), pGEM 3zf with Fe3+ and DTT (3), pGEM 3zf,
Fe3+, DTT and recombinant FhePrx [880 ng] (4), pGEM 3zf, Fe3+, Ascorbic acid and recombinant FhePrx [880 ng] (5), pGEM 3zf, Fe 3+, DTT, and
recombinant F. hepatica cathepsin L [1.4 lg] (6). The nicked (n) and supercoiled (s.c) form of plasmid are indicated by arrows. (B) Speciﬁc activity of
FhePrx determined by NADPH (0.25 mM) consumption. Hydrogen peroxide at a concentration of 0.25 mM was provided as substrate. FhePrx,
recombinant FhePrx, TR, E. coli thioredoxin and Trx, E. coli thioredoxin reductase. Values are the means of three independent experiments.
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absence of thioredoxin.
Peroxiredoxins of the parasitic helminth S. mansoni (SmPrx
2 and SmPrx 3) can utilise glutathione and glutathione reduc-
tase in addition to the thioredoxin system to provide reducing
equivalents [19,29]. Therefore FhePrx, which is 67% identical
to SmPrx 2 on the amino acid level, was tested for glutathione
aﬃnity. We found that recombinant FhePrx was not active
with glutathione (concentration ranging from 0.1 mM to
1 mM) and glutathione reductase (0.2 U) (Fig. 3B) as the addi-
tion of FhePrx failed to increase activity over the background
rate of NADPH consumption. By preparing truncated recom-
binant versions of SmPrx 2 and SmPrx 3, Sayed and Williams
[29] showed that the aﬃnity for glutathione was dependent on
the 22 amino acid C-terminal tail. In addition, another schisto-
some Prx, SmPrx 1, that lacks this C-terminal tail exhibited no
aﬃnity for glutathione [29]. In the Prx II group of peroxiredox-
ins, which includes SmPrx2 and FhePrx, the C-terminus is
known to form a well-ordered helix, which stabilizes the C-ter-
minal arm and reduces mobility [29,33]. The FhePrx C-termi-nal tail contains the conserved Tyr-Phe motif at residues 89
and 90, and is predicted to form a helical structure from resi-
dues 183–194 by the PredictProtein server [www.predictpro-
tein.org, Ref. 27]. However, the C-terminal tails of SmPrx 2
and FhePrx are only 55% identical on the amino acid level
and this sequence variation between the S. mansoni and F.
hepatica enzymes may account for the diﬀerence in C-terminal
arm mobility, resulting in diﬀerences in glutathione aﬃnity.
3.3. Steady-state enzyme kinetics and sensitivity to hydrogen
peroxide
Prxs from various species can react with diﬀerent hydroper-
oxides, although their eﬃciencies may diﬀer between substrates
[17]. FhePrx displayed saturable Michaelis–Menten type kinet-
ics with the substrates hydrogen peroxide, cumene hydroper-
oxide and tu-butyl hydroperoxide (Table 1). The kcat/Km
values for the substrates hydrogen peroxide and cumene
hydroperoxide were similar, whereas the value for t-butyl
hydroperoxide was slightly lower. The kinetic measurements
for all three substrates were consistent with previously
Table 1
Enzyme kinetics for recombinant FhePrx with various hydroperoxides
Km (lM) kcat (s
1) kcat/Km (M
1 s1)
H2O2 30.0 15.8 5.2 · 105
Cumene hydroperoxide 12.7 6.3 5.2 · 105
t-Butyl hydroperoxide 18.6 7.6 4.1 · 105
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Fig. 4. Steady-state kinetics for FhePrx at varying concentrations of
thioredoxin (A) and susceptibility of FhePrx to inactivation by H2O2
(B). (A) The enzyme-normalized reciprocal initial velocities are plotted
against the reciprocal molarities of hydrogen peroxide. Thioredoxin
concentrations are 5 lm (diamond), 7.5 lm (square), 10 lm (triangle)
and 20 lm (X). (B) The time course of NADPH (0.25 mM) oxidation
by recombinant FhePrx coupled with E. coli thioredoxin (10 lM) and
thioredoxin reductase (2 U) is shown for H2O2 concentrations of
0 mM (plus sign), 0.5 mM (diamond), 1.0 mM (square), 2.5 mM
(triangle), 5.0 mM (·), 7.5 mM (· with bar), and 10 mM (closed circle).
(C) FhePrx is sensitive to over-oxidation. The reaction rates from (B)
were plotted over time at the varying hydrogen peroxide concentra-
tions, then slopes of this data were plotted against reciprocal substrate
(hydrogen peroxide) concentrations.
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minth parasites [17].
The steady-state kinetics of FhePrx were analysed by mea-
suring initial rates of FhePrx activity using varying concentra-
tions of substrates hydrogen peroxide and reduced
thioredoxin. Two substrate enzyme reactions can be described
by the equation of Dalziel (1) [10].
E=v0 ¼ /0 þ /1=½A þ /2=½B þ /1;2=½A½B ð1Þ
where E is total enzyme molarity, v0 is initial rate, A is concen-
tration of hydrogen peroxide, B is concentration of thiore-
doxin, and /0, /1, /2 and /1,2 are constants associated with
the enzyme–substrate aﬃnity. The results were plotted as total
enzyme molarity divided by initial rate versus the reciprocal of
the hydrogen peroxide concentration (Fig. 4A). With typical
peroxidase kinetics, regression lines of the primary data are
parallel, however in Fig. 4A the lines are convergent. In sec-
ondary plots, the slopes and intercepts of the curves from
the primary data were plotted against the reciprocal of the re-
duced thioredoxin concentration and values for constants /0,
/1, /2, and /1,2 were derived [10]. The ﬁrst order rate constant
/0 is the reciprocal of kcat, in non-saturable kinetics, kcat ap-
proaches inﬁnity, and the value of the reciprocal is zero. The
/0 value obtained for FhePrx is 0.0538 s and therefore ﬁnite,
supporting previous conclusions that FhePrx is saturable and
has Michaelis–Menten type kinetics. The constant /1 refers
to the aﬃnity of the enzyme for the hydrogen peroxide sub-
strate and /2 refers to aﬃnity of the oxidized enzyme for re-
duced thioredoxin. The value for /1 for FhePrx is
0.105 lM s1 and is relatively low compared to that reported
for Prx enzymes of schistosomes [28], bacteria and protozoa
[16]. The signiﬁcance of this relative low rate of association
of reduced FhePrx for hydrogen peroxide is unknown, but
these rates can diﬀer by several orders of magnitude between
Prxs of various species and may reﬂect diﬀerences in the levels
of substrate in the particular microenvironment in which the
enzymes function. Alternatively, the reported rates of associa-
tion for hydrogen peroxide for Prxs of various sources may
also be an artifact of recombinant protein production and/or
the capacity of these proteins to form dimers or decamers.
However, the /2 constant of 0.173 lM s
1 for the F. hepatica
enzyme is similar to values for other peroxiredoxins, indicating
that regeneration of the reduced enzyme likely occurs at a sim-
ilar rate [17]. The third order rate constant /1,2 was calculated
as 12.42 lM2 s1, it is surprising that our analysis yields a term
for a ternary complex as nearly all kinetic evidence for reaction
order in peroxiredoxins suggest that the detoxiﬁcation of
hydrogen peroxide occurs as two half reactions [17]. There
are two possible explanations for deviation from a typical dou-
ble displacement mechanism: (1) thioredoxin interacts with Prx
before hydrogen peroxide can be attacked, in which case a type
of ternary complex is formed. Thioredoxin certainly does inter-
act with Prx, but all experimental evidence to date indicates
that the function of thioredoxin is to provide reducing powerin the regeneration of Prx [4] and no evidence of an intermedi-
ate in which Prx is interacting with both substrates
simultaneously has been reported (2) Prx has an apparent sin-
gle-displacement mechanism, which deviates from double dis-
placement mechanism for a biologically signiﬁcant reason.
There is precedence for deviation from typical peroxidase
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mitochondrial tnpx of Leishmania infantum [17] do not con-
form to a double displacement mechanism. Reasons for a
change in kinetic pattern could be (1) enzymatic activity is
dependent on decameric versus dimeric conformation [17,33]
and conformational changes of recombinant Prx versus native
molecules are responsible, (2) sensitivity to hydrogen peroxide
substrate, especially at higher concentrations of thioredoxin,
alters the rates or (3) as the coupled enzyme reaction relies
on the E. coli-derived thioredoxin and thioredoxin peroxidase,
the use of the F. hepatica enzymes could result in a diﬀerent
pattern.
Many eukaryotic 2-Cys Prxs are sensitive to high levels of
hydrogen peroxide due to over-oxidation of the peroxidatic
cysteine to sulﬁnic acid, which cannot be rapidly reduced
again, resulting in inactivation of the enzyme [17,32,33]. In
the presence of high concentrations of hydrogen peroxide the
eﬀective concentration of the enzyme is reduced. We observed
that FhePrx activity is subject to over-oxidation at hydrogen
peroxide concentrations of 500 lM and greater (Fig. 4B). We
further investigated the sensitivity of FhePrx to over-oxidation
by determining the reaction rates of the enzyme at increasing
hydrogen peroxide concentration. The rates of inactivation,
determined by the ratio of the rate at each given time to the ini-
tial rate, were plotted against the concentration of hydrogen
peroxide (Fig. 4C). The steep slope of the curve is consistent
with an enzyme that is rapidly inactivated and is comparable
to data reported for sensitive Prxs such as the schistosome
Prx 2 and Prx 3 and human Prx 1 [29,32].
The data shows that, like other peroxiredoxins, the capacity
of the FhePrx to scavenge hydrogen peroxide (kcat/Km =
5.2 · 105 M1 s1) is one or two orders of magnitude lower
than other peroxidases. However, given that F. hepatica para-
sites lack catalase activity and express minimal levels of gluta-
thione peroxidase [1,2,23] the Prx system must be a
requirement for detoxiﬁcation of metabolically-produced
hydrogen peroxide in this parasite. The cells of the liver ﬂuke
may be under particular oxidative stress during migration in
the host at which time (approximately 8 weeks) metabolic pro-
cesses (catabolism of host proteins and anabolism of parasite
proteins) result in growth from <1 mm to >1.5 cm in length
[11]. The high aﬃnity of FhePrx for hydrogen peroxide, the
concentration required to obtain half maximal rate (Km) is
30 lM, coupled with the high abundance of enzyme in parasite
cells, is suﬃcient to maintain peroxide levels below toxic levels,
120–150 lM [25]. Recently, Sayed and Williams [30] demon-
strated that knocking down Prx activity by interference
RNA techniques in larvae of S. mansoni resulted in an increase
in parasite mortality by seven-fold; although Prx 1 dsRNA was
used for silencing, reduction in both Prx 1 and Prx 2 expression
was observed.
Parasite Prxs are of further interest because of their possible
function in maintaining the host–parasite relationship. The
FhePrx is abundant in the parasite tissues, and is also secreted
by the parasite [this study and references 13, 18 and 26], despite
lacking a signal sequence, which suggests that the anti-oxidant
functions outside the parasite. We and others have speculated
that this function may include the inactivation of ROS released
by immune eﬀector cells such as eosinophils, neutrophils and
macrophages, although there is no supporting evidence for this
function [2,17,26]. However, we have recently shown that
injection of partially puriﬁed native FhePrx or recombinantFhePrx into mice induced the recruitment of alternatively acti-
vated host macrophages [13]. The mechanism by which FhePrx
exerts its function on macrophages needs to be elucidated but
this may be via binding to speciﬁc surface receptors and/or
drawing on emerging new functions of Prx in signal transduc-
tion [12], altering hydrogen peroxide levels on the extracellular
surface of the cells.
Enzymes associated with antioxidant defence in parasites are
considered targets at which new drug treatments could be
developed, hence, it is important that we understand the bio-
chemistry of these molecules. However, the high level of struc-
tural conservation between the Prx of F. hepatica and its hosts
(approximately 65% at the overall amino acid levels and al-
most 100% in the catalytic motifs) and biochemical similarities
do not augur well for selective chemotherapy. The alternative
approach of disrupting the function of these molecules via vac-
cine-induced immune responses may prove more successful,
particularly given the potential functions in host–parasite
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